A high dividend yield can be the ultimate retirement holding. Or it can be a trap.
Today, I’m going to show you five stocks with mouth-watering yields of between 6% and 23% that are tomorrow’s dividend disasters. If you own shares in any of these firms, sell them now.
stock market analysis software: HCI Group, Inc.(HCI)
- [By Jim Robertson]
Small cap Florida insurance stock HCI Group Inc (NYSE: HCI) has taken a hit with shares down around 21% over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 2.74%on Friday when it became clear that it would not be as catastrophic as feared:
stock market analysis software: Internationa Flavors & Fragrances, Inc.(IFF)
- [By Lee Jackson]
International Flavors & Fragrances Inc. (NYSE: IFF) is yet another company that hit our screens witha 10% institutional owner buying stock twice last week. Winder Investment purchased a total of 70,000 shares. At $128.38per share, the total for the trade was a solid $9 million. Later in the week the company stepped in again and bought another100,000 shares at prices between $129.47 and 132.20 apiece. The total for that buy was posted at $13 million. The shares closed trading last Friday at $133.19, so some timely buys for sure. The 52-week trading range is $112.91 to $143.64. The consensus price target is $131.40.
stock market analysis software: Allscripts Healthcare Solutions, Inc.(MDRX)
- [By Benzinga News Desk]
Goldman Sachs (NYSE: GS) has at least one billion reasons to hope President Trump’s paring back of Dodd-Frank will include the Volcker Rule: Link
10:30 a.m. Dallas Fed Manufacturing Business Index
11:30 a.m. 6-Month Bill Auction
11:30 a.m. 3-Month Bill Auction
1 p.m. 2-Year Note Auction
1:15 p.m. Chicago Fed President Evans Speaks
6:30 p.m. FOMC Member Kaplan Speaks
Piper Jaffray upgraded Best Buy Co (NYSE: BBY) from Neutral to Overweight
Wells Fargo upgraded Allscripts Healthcare (NASDAQ: MDRX) from Market Perform to Outperform
Mizuho upgraded Universal Health Service (NYSE: UHS) from Neutral to Buy
Piper Jaffray downgraded The Michaels Companies (NASDAQ: MIK) from Overweight to Neutral
JMP Securities downgraded KB Home (NYSE: KBH) from Market Outperform to Market Perform
Raymond James downgraded Sierra Wireless Inc. (NASDAQ: SWIR) from Outperform to Market Perform
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email email@example.com.
- [By Monica Gerson]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.
Texas Instruments Incorporated (NASDAQ: TXN) Fri 7/1 62.0 Puts (Wkly) Sweep: 1426 @ ASK $1.24: 1426 traded vs 0 OI: Earnings 7/27 $61.86 Ref
Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) Jul16 13.0 Puts Sweep: 500 @ ASK $0.45: 500 traded vs 0 OI: Earnings 8/2 $13.07 Ref
Intel Corporation (NASDAQ: INTC) Jul16 30.0 Puts: 7500 @ ASK $0.26: 7658 traded vs 47k OI: Earnings 7/20 $32.07 Ref
Ares Capital Corporation (NASDAQ: ARCC) Dec16 16.0 Puts Sweep: 963 @ ASK $2.75: 974 traded vs 18 OI: Earnings 8/2 $14.45 Ref
LinkedIn Corp (NYSE: LNKD) Aug16 115 Puts: 600 @ ASK $4.05: 615 traded vs 386 OI: $132.12 Ref
Posted-In: Unusual Put OptionsNews Options Markets
stock market analysis software: American Software, Inc.(AMSWA)
- [By Lisa Levin]
Shares of American Software, Inc. (NASDAQ: AMSWA) were down 12 percent to $10.58. American Software reported preliminary Q4 adjusted earnings of $0.09 per share on revenue of $26.3 million.
stock market analysis software: Smith & Nephew SNATS, Inc.(SNN)
- [By Charles Carlson, CEO and Portfolio Manager, Horizon Investment Services]
For investors looking for growth but also income, I especially like three health-care related stocksFresenius Medical (FMS), Novo Nordisk (NVO), and Smith & Nephew (SNN).
stock market analysis software: Ono Pharmaceutical Co., Ltd. (OPHLF)
- [By SEEKINGALPHA.COM]
Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.